Bris­tol My­ers in­vests $35M in­to Im­mat­ics; Fi­bro­Gen names new CEO

Bris­tol My­ers Squib has made a $35 mil­lion in­vest­ment in­to the T cell-fo­cused biotech Im­mat­ics, pur­chas­ing over 2.4 mil­lion shares.

The move will al­low for Bris­tol My­ers to ap­point some­one to Im­mat­ics’ sci­en­tif­ic ad­vi­so­ry board. But no names were im­me­di­ate­ly brought for­ward, and no in­di­ca­tions for what the funds will be used for were im­me­di­ate­ly avail­able.

“This in­vest­ment is fur­ther tes­ti­mo­ny to the strength of the re­la­tion­ship and of our dif­fer­en­ti­at­ed plat­form tech­nolo­gies that are the foun­da­tion of our TCR-based cell ther­a­pies and bis­pecifics,” said Im­mat­ics CEO Harpreet Singh in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER